Co-Authors
This is a "connection" page, showing publications co-authored by ROBERT COLEMAN and NICOLE FLEMING.
Connection Strength
1.643
-
Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022 07; 166(1):50-56.
Score: 0.219
-
Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
Score: 0.203
-
A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy. Cancers (Basel). 2021 Feb 09; 13(4).
Score: 0.200
-
Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.
Score: 0.197
-
Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432.
Score: 0.171
-
Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
Score: 0.169
-
Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017 10; 147(1):41-46.
Score: 0.157
-
Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89.
Score: 0.054
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.048
-
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
Score: 0.047
-
Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep. 2019 11 26; 9(1):17589.
Score: 0.046
-
Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019 09; 154(3):524-530.
Score: 0.045
-
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget. 2019 May 28; 10(37):3533-3546.
Score: 0.045
-
When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System. Int J Gynecol Cancer. 2018 10; 28(8):1485-1490.
Score: 0.043